Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer ' s disease: the MADE Phase II, three-arm RCT

Minocycline is an anti-inflammatory drug and protects against the toxic effects of β-amyloid in vitro and in animal models of Alzheimer ' s disease. To the best of our knowledge, no randomised placebo-controlled clinical trials in patients with Alzheimer ' s disease looking at the efficacy and tolerability of minocycline have been carried out.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news